

### **Amendments to the Claims**

Please amend the claims to read as follows:

1-104. (Canceled)

105. (New) A method of selecting a dose of an anti-oxidant composition for administration to a human, the method comprising assessing occurrence in the human's genome of disorder-associated polymorphisms in a superoxide dismutase gene and in a catalase gene of the human, whereby each occurrence of a disorder associated polymorphism indicates an increased dose of the composition.

106. (New) The method of claim 105, further comprising assessing occurrence in the human's genome of disorder-associated polymorphisms in at least one third gene selected from the group consisting of the genes encoding glutathione peroxidase, paraoxonase, NAD(P)H:quinone oxidoreductase, epoxide hydrolase, myeloperoxidase, tumor necrosis factor alpha, NADH/NADPH oxidase p22 subunit, nitric oxide synthase, cytochrome P450, ApoE4, and cystathionine betasynthase.

107. (New) The method of claim 106, further comprising assessing occurrence in the human's genome of disorder-associated polymorphisms in at least two of the third genes.

108. (New) The method of claim 106, further comprising assessing occurrence in the human's genome of disorder-associated polymorphisms in at least four of the third genes.

109. (New) The method of claim 106, further comprising assessing occurrence in the human's genome of disorder-associated polymorphisms in at least six of the third genes.